Daily non-political popular news in brief.

Patients who receive drug-eluting stents should continue antiplatelet medications

01-16-2007 · EurekAlert!

Patients who have had drug-eluting stents inserted to prop open blocked coronary arteries should continue to take medications to reduce the risk of blood clots for at least one year after the stent is inserted, a new scientific advisory recommends.

Keywords: patients, receive, drug-eluting, stents, continue, antiplatelet, medications, patient, drug, eluting, stent, medication

« Previous | Next »

Similar news on "Patients who receive drug-eluting stents should continue antiplatelet medications":

SCAI issues clinical alert on drug-eluting stents and late thrombosis
01-11-2007 · EurekAlert!
The Society for Cardiovascular Angiography and Interventions (SCAI) today released a clinical alert advising physicians on practical steps for reducing the risk of a rare but serious complication associated with drug-eluting stents. The document follows hearings held by the FDA's Circulatory Systems Device Panel. SCAI's clinical alert focuses on careful patient selection, meticulous stent implantation, and consistent use of medications to prevent the delayed formation of blood clots that can block blood flow to the heart.
Similar news · Read more »
Bioabsorbable stent shows excellent performance
03-24-2007 · EurekAlert!
The use of slow-release drugs in stents (drug-eluting stents) has dramatically reduced restenosis rates after percutaneous coronary intervention. However, these permanent metal devices may impair coronary imaging, predispose patients to late stent thrombosis, prevent positive remodeling and hinder revascularization. A study presented today at the American College of Cardiology's Innovation in Intervention: i2Summit assesses the safety and performance of a bioabsorbable stent that, if effective, could eliminate several of the problems associated with metallic stents.
Similar news · Read more »
Phone-based therapy eases depression long term
03-22-2007 · EurekAlert!
When people receive brief telephone-based psychotherapy soon after starting antidepressant medication, strong positive effects may continue 18 months after their first session. So concludes a Group Health study in the April Journal of Consulting and Clinical Psychology. With close to 400 patients, this is the largest study yet of psychotherapy delivered by phone. It’s also the first to study the effectiveness of combining phone-based therapy with antidepressant drug treatment as provided in everyday medical practice.
Similar news · Read more »
Studies led by Rhode Island Hospital confirm safety and efficacy
11-17-2006 · EurekAlert!
Following two studies of patients who were treated with cardiac stents, physicians at Rhode Island Hospital continue to recommend drug-eluting stents as a safe and effective treatment.
Similar news · Read more »
Second generation drug-eluting stent system challenges current gold standard
03-24-2007 · EurekAlert!
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.
Similar news · Read more »
Second-generation drug-eluting stent system challenges current gold standard
03-24-2007 · EurekAlert!
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.
Similar news · Read more »
Studies highlight 'real world' use, safety of drug-eluting stents
03-26-2007 · EurekAlert!
Research presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent -- a dangerous complication -- and adherence and responsiveness to anti-clotting medication.
Similar news · Read more »
Patients can't recall their medications to tell doctors
10-11-2007 · EurekAlert!
Doctors depend on patients to accurately tell them what drugs they are taking in out-patient visits. But Northwestern University found nearly 50 percent of patients taking antihypertensive drugs were unable to accurately name a single one of their medications. Thus, doctors can't monitor if a drug is working or know about potential adverse interactions.
Similar news · Read more »
Mayo Clinic study shows drug-eluting stent use in heart patients determined more by insurance type
03-27-2007 · EurekAlert!
If you want the best technology available to relieve blocked blood flow to the heart, the choice is a drug-eluting stent. And you are most likely to obtain the drug-eluting stent for reasons that have nothing to do with your medical condition, a new Mayo Clinic study shows.
Similar news · Read more »
Drug eluting nanostructured coatings enable targeted drug therapy for orthopedic patients
05-20-2007 · EurekAlert!
Drug delivery systems have progressed from the teaspoon to time-release capsules to drug-eluting stents. Nanotechnology promises yet another advance by delivering therapeutic agents at desired rates exactly where needed in the body. In a paper presented at the NSTI Nanotech 2007 Conference, researchers at the University of California, San Francisco demonstrate how they have created nanotubes from biocompatible metal oxides that can hold therapeutic proteins or drugs and deliver these agents in a highly-controlled manner.
Similar news · Read more »